An interventional study of Endovascular embolization in Meningioma, sponsored by St. Olavs Hospital. Recruiting at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by St. Olavs Hospital · Not applicable, Interventional, and Treatment
The natural course for meningioma suggests that a majority will grow over time. Treatment is usually indicated in growing or symptomatic meningiomas. Surgery is usually primary treatment, but there is a significant risk of adverse effects. Stereotactic radiotherapy is most often reserved to treat relapses after surgery, and except for surgery and radiotherapy there are no other established treatment methods. Endovascular embolization may be used in selected cases as a preoperative adjunct to reduce intraoperative bleeding. There is a need for more treatment options in patients with meningioma, both in uncomplicated, asymptomatic cases and in more complex cases. The aim of this study is to assess radiological and clinical results of therapeutic endovascular embolization for meningioma
255 studies on the registry are indexed under Meningioma; 85 are open to participants now.
This study's planned enrollment of 30 is below the median of 40 across 180 interventional studies indexed under Meningioma.
Browse Meningioma studies →St. Olavs Hospital is the lead sponsor of 171 studies on the registry; 29 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Endovascular embolization
Therapeutic endovascular embolization in general anesthesia
Change in radiological tumor volume from baseline
Volumetric segmentation of tumor volume
Time frame: At 1 year, 3 year and 5 year
Number of participants undergoing re-intervention for meningioma or treatment complications
Surgery or radiotherapy
Time frame: 10 years
Number of participants with epileptic seizures
Time frame: 10 years
Number of participants with moderate or severe procedure related complications within 30 days
Landriel Ibanez classification (grade 3 or 4 complications)
Time frame: 30 days
Change in generic health-related quality of life from baseline
EuroQol-5D 3L (EQ-5D 3L)
Time frame: At 1 months and 6 months
Change in disease-specific quality of life from baseline
The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire
Time frame: At 1 months and 6 months
Change in domain-specific quality of life from baseline
The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-BN20 questionnaire
Time frame: At 1 months and 6 months
Change in neurological function
National Institutes of Health Stroke Scale (NIHSS)
Time frame: At 1 month
Number of participants with adverse events
Landriel Ibanez classification
Time frame: 30 days
Number of participants returning to work
Time frame: At 1 months and 6 months
Loss of functional level from baseline
\>10 points in Karnofsky performance status
Time frame: At 1 month and 6 months
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2022 (actual). Primary completion is estimated for Aug 2027, 58 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.